HilleVax (NASDAQ:HLVX) Trading Down 0.9% - Time to Sell?

Key Points

• HilleVax, Inc. shares fell by 0.9% to $2.09, with a 26% decline in trading volume compared to its average session.
• The company reported a quarterly earnings per share of (-$0.12), surpassing expectations by $0.25, and is projected to have a -2.64 EPS for the current fiscal year.
• Institutional investors hold 86.42% of HilleVax's stock, with significant recent investments from firms such as Federated Hermes Inc. and AQR Capital Management LLC.

Shares of HilleVax, Inc. (NASDAQ:HLVX - Get Free Report) traded down 0.9% on Wednesday . The stock traded as low as $2.08 and last traded at $2.09. 87,336 shares were traded during mid-day trading, a decline of 26% from the average session volume of 117,492 shares. The stock had previously closed at $2.11.

HilleVax Stock Performance

The company has a market capitalization of $102.29 million, a P/E ratio of -0.95 and a beta of 0.77. The firm has a 50 day moving average price of $2.00 and a two-hundred day moving average price of $1.86.

HilleVax (NASDAQ:HLVX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.25. On average, equities analysts expect that HilleVax, Inc. will post -2.64 earnings per share for the current year.

Institutional Trading of HilleVax

Hedge funds and other institutional investors have recently modified their holdings of the company. Callan Family Office LLC acquired a new stake in shares of HilleVax in the 1st quarter valued at about $28,000. Federated Hermes Inc. increased its position in shares of HilleVax by 128.3% in the first quarter. Federated Hermes Inc. now owns 24,429 shares of the company's stock valued at $35,000 after acquiring an additional 13,728 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of HilleVax in the first quarter valued at about $36,000. AQR Capital Management LLC increased its position in shares of HilleVax by 38.0% in the first quarter. AQR Capital Management LLC now owns 33,495 shares of the company's stock valued at $49,000 after acquiring an additional 9,228 shares during the last quarter. Finally, Bank of Montreal Can increased its position in shares of HilleVax by 47.1% in the fourth quarter. Bank of Montreal Can now owns 35,763 shares of the company's stock valued at $74,000 after acquiring an additional 11,459 shares during the last quarter. Institutional investors and hedge funds own 86.42% of the company's stock.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.